-
1
-
-
85055522508
-
-
Erbitux (cetuximab) [package insert], NJ: Bristol-Myers Squibb
-
Erbitux (cetuximab) [package insert]. Princeton, NJ: Bristol-Myers Squibb; 2007.
-
(2007)
Princeton
-
-
-
2
-
-
79959835735
-
-
Vectibix (panitumumab) [product monograph], Ontario, Canada: Amgen
-
Vectibix (panitumumab) [product monograph]. Mississauga, Ontario, Canada: Amgen; 2008.
-
(2008)
Mississauga
-
-
-
3
-
-
85030408649
-
-
Iressa (gefitinib) [package insert], Ontario, Canada: Astra Zeneca
-
Iressa (gefitinib) [package insert]. Mississauga, Ontario, Canada: Astra Zeneca; 2011.
-
(2011)
Mississauga
-
-
-
4
-
-
79951760967
-
-
Tarceva (erlotinib) [package insert], Ontario, Canada: Hoffman-La Roche Ltd
-
Tarceva (erlotinib) [package insert]. Mississauga, Ontario, Canada: Hoffman-La Roche Ltd; 2009.
-
(2009)
Mississauga
-
-
-
5
-
-
84872844201
-
The impact of dermatological toxicities of anti-cancer therapy on the dermatological quality of life of cancer patients
-
Ra HS, Shin SJ, Kim JH, Lim H, Cho BC, Roh MR. The impact of dermatological toxicities of anti-cancer therapy on the dermatological quality of life of cancer patients. J Eur Acad Dermatol Venereol 2013;27:e53-9.
-
(2013)
J Eur Acad Dermatol Venereol
, vol.27
, pp. e53-e59
-
-
Ra, H.S.1
Shin, S.J.2
Kim, J.H.3
Lim, H.4
Cho, B.C.5
Roh, M.R.6
-
6
-
-
84880865947
-
Impact of dermatologic adverse events on quality of life in 283 cancer patients: A questionnaire study in a dermatology referral clinic
-
Rosen AC, Case EC, Dusza SW, Balagula Y, Gordon J, West DP, et al. Impact of dermatologic adverse events on quality of life in 283 cancer patients: a questionnaire study in a dermatology referral clinic. Clin Dermatol 2013;14:327-33.
-
(2013)
Clin Dermatol
, vol.14
, pp. 327-333
-
-
Rosen, A.C.1
Case, E.C.2
Dusza, S.W.3
Balagula, Y.4
Gordon, J.5
West, D.P.6
-
7
-
-
84866646369
-
Skin toxicity and quality of life in patients with metastatic colorectal cancer during first-line panitumumab plus FOLFIRI treatment in a single-arm phase II study
-
Thaler J, Karthaus M, Mineur L, Greil R, Letocha H, Hofheinz R, et al. Skin toxicity and quality of life in patients with metastatic colorectal cancer during first-line panitumumab plus FOLFIRI treatment in a single-arm phase II study. BMC Cancer 2012;12: 438.
-
(2012)
BMC Cancer
, vol.12
, pp. 438
-
-
Thaler, J.1
Karthaus, M.2
Mineur, L.3
Greil, R.4
Letocha, H.5
Hofheinz, R.6
-
8
-
-
38549142436
-
Impact and management of skin toxicity associated with anti-epidermal growth factor receptor therapy: Survey results
-
Boone SL, Rademaker A, Liu D, Pfeiffer C, Mauro DJ, Lacouture ME. Impact and management of skin toxicity associated with anti-epidermal growth factor receptor therapy: survey results. Oncology 2007;72:152-9.
-
(2007)
Oncology
, vol.72
, pp. 152-159
-
-
Boone, S.L.1
Rademaker, A.2
Liu, D.3
Pfeiffer, C.4
Mauro, D.J.5
Lacouture, M.E.6
-
9
-
-
36849093857
-
Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab associated acne-like eruption
-
Scope A, Agero AL, Dusza SW. Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab associated acne-like eruption. J Clin Oncol 2007;25: 5390-6.
-
(2007)
J Clin Oncol
, vol.25
, pp. 5390-5396
-
-
Scope, A.1
Agero, A.L.2
Dusza, S.W.3
-
10
-
-
66749140972
-
A prospective randomized trial of topical pimecrolimus for cetuximab-associated acnelike eruption
-
Scope A, Lieb JA, Disza SW. A prospective randomized trial of topical pimecrolimus for cetuximab-associated acnelike eruption. J Am Acad Dermatol 2009;61:614-20.
-
(2009)
J Am Acad Dermatol
, vol.61
, pp. 614-620
-
-
Scope, A.1
Lieb, J.A.2
Disza, S.W.3
-
11
-
-
84855919382
-
The management of EGFR inhibitor adverse events: A case series and treatment paradigm
-
Wnorowski AM, de Souza A, Chachoua A, Cohen DE. The management of EGFR inhibitor adverse events: a case series and treatment paradigm. Int J Dermatol 2012;51:223-32.
-
(2012)
Int J Dermatol
, vol.51
, pp. 223-232
-
-
Wnorowski, A.M.1
De Souza, A.2
Chachoua, A.3
Cohen, D.E.4
-
12
-
-
84882889101
-
Erlotinib-related skin toxicities: Treatment strategies in patients with metastatic non small cell lung cancer
-
Kiyohara Y, Yamazaki N, Kishi A. Erlotinib-related skin toxicities: treatment strategies in patients with metastatic non small cell lung cancer. J Am Acad Dermatol 2013;69: 463-72.
-
(2013)
J Am Acad Dermatol
, vol.69
, pp. 463-472
-
-
Kiyohara, Y.1
Yamazaki, N.2
Kishi, A.3
-
13
-
-
42649145667
-
Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer
-
Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008;26:1626-34.
-
(2008)
J Clin Oncol
, vol.26
, pp. 1626-1634
-
-
Amado, R.G.1
Wolf, M.2
Peeters, M.3
Van Cutsem, E.4
Siena, S.5
Freeman, D.J.6
-
14
-
-
34547586714
-
Insights into the pathophysiology and management of dermatologic toxicities to EGFR-targeted therapies in colorectal cancer
-
Lacouture ME. Insights into the pathophysiology and management of dermatologic toxicities to EGFR-targeted therapies in colorectal cancer. Cancer Nurs 2007;30:S17-26.
-
(2007)
Cancer Nurs
, vol.30
, pp. S17-26
-
-
Lacouture, M.E.1
-
15
-
-
4344646459
-
Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer
-
Perez-Soler R, Chachoua A. Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol 2004;22:3238-47.
-
(2004)
J Clin Oncol
, vol.22
, pp. 3238-3247
-
-
Perez-Soler, R.1
Chachoua, A.2
-
16
-
-
84984568870
-
MASCC skin toxicity study group. Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities
-
Lacouture ME, Anadkat MJ, Bensadoun RJ, Bryce J, Chan A, Epstein JB, et al. MASCC Skin Toxicity Study Group. Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities. Support Care Cancer 2011;19:1079-95.
-
(2011)
Support Care Cancer
, vol.19
, pp. 1079-1095
-
-
Lacouture, M.E.1
Anadkat, M.J.2
Bensadoun, R.J.3
Bryce, J.4
Chan, A.5
Epstein, J.B.6
-
17
-
-
78751622165
-
Clinical presentation and management of dermatological toxicities of epidermal growth factor receptor inhibitors
-
Balagula Y, Garbe C, Myskowski P, Haushild A, Rapoport B, Boers-Doets CB, et al. Clinical presentation and management of dermatological toxicities of epidermal growth factor receptor inhibitors. Int J Dermatol 2011;50:129-46.
-
(2011)
Int J Dermatol
, vol.50
, pp. 129-146
-
-
Balagula, Y.1
Garbe, C.2
Myskowski, P.3
Haushild, A.4
Rapoport, B.5
Boers-Doets, C.B.6
-
18
-
-
20844448897
-
HER1/EGFR inhibitor-associated rash: Future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum
-
Pérez-Soler R, Delord JP, Halpern A, Kelly K, Krueger J, Sureda BM, et al. HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum. Oncologist 2005;10:345-56.
-
(2005)
Oncologist
, vol.10
, pp. 345-356
-
-
Pérez-Soler, R.1
Delord, J.P.2
Halpern, A.3
Kelly, K.4
Krueger, J.5
Sureda, B.M.6
-
19
-
-
77951879709
-
Pimecrolimus cream 1% for the treatment of papulopustular eruption related to epidermal growth factor receptor inhibitors: A case series and a literature review of therapeutic approaches
-
Nikolaou V, Stratigos A, Antoniou C, Kiagia M, Nikolaou C, Katsambas A, et al. Pimecrolimus cream 1% for the treatment of papulopustular eruption related to epidermal growth factor receptor inhibitors: a case series and a literature review of therapeutic approaches. Dermatology 2010;220:243-8.
-
(2010)
Dermatology
, vol.220
, pp. 243-248
-
-
Nikolaou, V.1
Stratigos, A.2
Antoniou, C.3
Kiagia, M.4
Nikolaou, C.5
Katsambas, A.6
-
20
-
-
84875044772
-
Topical vitamin K1 may not be effective in preventing acneiform rash during cetuximab treatment in patients with metastatic colorectal cancer
-
Jo JC, Hong YS, Kim KP, Lee JL, Kim HJ, Lee MW, et al. Topical vitamin K1 may not be effective in preventing acneiform rash during cetuximab treatment in patients with metastatic colorectal cancer. Eur J Dermatol 2013;23: 77-82.
-
(2013)
Eur J Dermatol
, vol.23
, pp. 77-82
-
-
Jo, J.C.1
Hong, Y.S.2
Kim, K.P.3
Lee, J.L.4
Kim, H.J.5
Lee, M.W.6
-
21
-
-
47849098042
-
Acitretin for treatment of EGFR inhibitor-induced cutaneous toxic effects
-
Pomerantz RG, Chirinos RE, Falo LD, Geskin LJ. Acitretin for treatment of EGFR inhibitor-induced cutaneous toxic effects. Arch Dermatol 2008;144:949-50.
-
(2008)
Arch Dermatol
, vol.144
, pp. 949-950
-
-
Pomerantz, R.G.1
Chirinos, R.E.2
Falo, L.D.3
Geskin, L.J.4
-
22
-
-
77950495095
-
Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-emptive skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer
-
Lacouture ME, Mitchell EP, Piperdi B, Pillai MV, Shearer H, Iannotti N, et al. Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-emptive skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer. J Clin Oncol 2010;28:1351-7.
-
(2010)
J Clin Oncol
, vol.28
, pp. 1351-1357
-
-
Lacouture, M.E.1
Mitchell, E.P.2
Piperdi, B.3
Pillai, M.V.4
Shearer, H.5
Iannotti, N.6
-
23
-
-
84984570566
-
How well does the MESTT correlate with CTCAE scale for the grading of dermatological toxicities associated with oral tyrosine kinase inhibitors
-
Chan A, Tan EH. How well does the MESTT correlate with CTCAE scale for the grading of dermatological toxicities associated with oral tyrosine kinase inhibitors? Support Care Cancer 2011;19:1667-74.
-
(2011)
Support Care Cancer
, vol.19
, pp. 1667-1674
-
-
Chan, A.1
Tan, E.H.2
-
24
-
-
3242881591
-
-
National Cancer Institute. Accessed September 9
-
National Cancer Institute. Common Toxicity Criteria for Adverse Events. Available from: URL: http://evs.nci.nih.gov/ ftp1/CTCAE/About.html. Accessed September 9, 2013.
-
(2013)
Common Toxicity Criteria for Adverse Events
-
-
-
25
-
-
35548969264
-
Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: An evolving paradigm in clinical management
-
Lynch T, Kim ES, Eaby B, Garey J, West DP, Lacouture M. Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management. Oncologist 2007;12:610-21.
-
(2007)
Oncologist
, vol.12
, pp. 610-621
-
-
Lynch, T.1
Kim, E.S.2
Eaby, B.3
Garey, J.4
West, D.P.5
Lacouture, M.6
-
26
-
-
84922703239
-
-
University Health Network. Accessed October 1
-
University Health Network. Our hospitals: Princess Margaret Cancer Center. Available from: URL: http://www.uhn.ca/corporate/ AboutUHN/OurHospitals/Pages/PMCC.aspx. Accessed October 1, 2013.
-
(2013)
Our Hospitals: Princess Margaret Cancer Center
-
-
-
27
-
-
84908418476
-
R core team. R: A language and environment for statistical computing
-
Accessed October , Vienna (Austria)
-
R Core Team. R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna (Austria). Available from: URL:http://www.R-project. org/. Accessed October 2013.
-
(2013)
R Foundation for Statistical Computing
-
-
-
28
-
-
34447129570
-
Correlation between development of rash and efficacy in patients treated with epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies
-
Wacker B, Nagrani T, Weinberg J, Witt K. Correlation between development of rash and efficacy in patients treated with epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies. Clin Cancer Res 2007; 13:3913-21.
-
(2007)
Clin Cancer Res
, vol.13
, pp. 3913-3921
-
-
Wacker, B.1
Nagrani, T.2
Weinberg, J.3
Witt, K.4
-
29
-
-
65749101493
-
Management of skin rash during EGFR-targeted monoclonal antibody treatment for gastrointestinal malignancies: Canadian recommendations
-
Melosky B, Burkes R, Rayson D, Alcindor T, Shear N, Lacouture M. Management of skin rash during EGFR-targeted monoclonal antibody treatment for gastrointestinal malignancies: Canadian recommendations. Curr Oncol 2009;16: 16-26.
-
(2009)
Curr Oncol
, vol.16
, pp. 16-26
-
-
Melosky, B.1
Burkes, R.2
Rayson, D.3
Alcindor, T.4
Shear, N.5
Lacouture, M.6
-
30
-
-
84875878144
-
A real life experience using panitumumab in chemo-refractory metastatic colorectal cancer patients: A retrospective analysis at the Jewish General Hospital, 2009-2012
-
Mamo A, Nogueira MC, Batist G, Palumbo M, Panasci L, Ferrario C, et al. A real life experience using panitumumab in chemo-refractory metastatic colorectal cancer patients: a retrospective analysis at the Jewish General Hospital, 2009-2012. Curr Oncol 2013;20:e107-12.
-
(2013)
Curr Oncol
, vol.20
, pp. e107-e112
-
-
Mamo, A.1
Nogueira, M.C.2
Batist, G.3
Palumbo, M.4
Panasci, L.5
Ferrario, C.6
-
31
-
-
84899981129
-
Panitumumab versus cetuximab in patients with chemotherapyrefractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): A randomised, multicentre, open-label, non-inferiority phase 3 study
-
Price TJ, Peeters M, Kim TW, Li J, Cascinu S, Ruff P, et al. Panitumumab versus cetuximab in patients with chemotherapyrefractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study. Lancet Oncol 2014;15:569-79.
-
(2014)
Lancet Oncol
, vol.15
, pp. 569-579
-
-
Price, T.J.1
Peeters, M.2
Kim, T.W.3
Li, J.4
Cascinu, S.5
Ruff, P.6
|